BiotechTube
Armatus Bio

Armatus Bio

Cambridge, United States· Est.
armatusbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $85M

Overview

Armatus Bio is a private, pre-clinical stage biotech pioneering vectorized RNAi therapeutics for rare neurological disorders. The company's core strategy involves engineering novel viral capsids to enable precise, durable delivery of RNAi payloads to target tissues, particularly the central and peripheral nervous systems. Founded in 2021 and based in Cambridge, MA, it is a pre-revenue company building a pipeline for high-unmet-need genetic diseases. Its work represents a convergence of gene therapy and RNAi technologies aimed at overcoming historical delivery challenges.

Neurological DisordersNeuromuscular Diseases

Technology Platform

Proprietary capsid engineering platform for AAV vectors designed to enable precise, durable delivery of RNAi payloads to the central nervous system, peripheral nervous system, and muscle tissue.

Funding History

2
Total raised:$85M
Series A$75M
Seed$10M

Opportunities

The high unmet need in rare genetic neurological diseases creates a receptive market for effective therapies.
A successfully validated CNS-delivery platform has immense value and can be applied to multiple disease programs, creating a pipeline-in-a-product opportunity.
The growing validation of RNAi as a therapeutic modality and AAV as a delivery vector provides a favorable scientific and regulatory environment.

Risk Factors

Significant technical risk remains in achieving effective and safe delivery to the human nervous system.
The company faces intense competition from other biotechs and pharma companies developing advanced gene therapy delivery technologies.
As a pre-revenue, private company, it is dependent on raising capital in competitive financial markets to fund expensive clinical development.

Competitive Landscape

Armatus operates in the competitive field of neurological gene therapy and RNAi delivery. Key competitors include Voyager Therapeutics, Lexeo Therapeutics, and UniQure, which are also engineering novel AAV capsids for CNS diseases. It also competes with oligonucleotide companies like Ionis Pharmaceuticals and Biogen developing antisense therapies for neurological conditions. Differentiation hinges on the specific performance and proprietary nature of its capsid technology.

More companies in RNA Therapeutics (non-mRNA) →More companies in United States →